These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11010656)

  • 21. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(223):64222-8. PubMed ID: 10339051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disqualification of a clinical investigator--FDA. Final rule.
    Fed Regist; 1997 Sep; 62(172):46875-6. PubMed ID: 10173286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(109):31143-61. PubMed ID: 10180130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a biological in vitro diagnostic product;" availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Mar; 64(44):11023-4. PubMed ID: 10557623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Import for export; reporting and recordkeeping requirements for unapproved or violative products imported for further processing or incorporation and subsequent export--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(226):64930-7. PubMed ID: 10338872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Guidance for Industry: On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test"; availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Apr; 64(78):20006-7. PubMed ID: 10558479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. State certification of mammography facilities. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(25):5446-69. PubMed ID: 11852885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Financial disclosure by clinical investigators--FDA. Final rule; action on petition for reconsideration.
    Fed Regist; 1998 Dec; 63(251):72171-81. PubMed ID: 10344800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laxative drug products for over-the-counter human use. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Jan; 64(19):4535-40. PubMed ID: 10557608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obtaining drugs from foreign markets.
    Shirk MB; Hale KN
    Am J Hosp Pharm; 1992 Nov; 49(11):2731-9. PubMed ID: 1471638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.